Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.110
+0.040 (3.74%)
At close: May 15, 2025, 4:00 PM
1.160
+0.050 (4.50%)
Pre-market: May 16, 2025, 7:18 AM EDT

Pyxis Oncology Statistics

Total Valuation

Pyxis Oncology has a market cap or net worth of $68.76 million. The enterprise value is -$16.83 million.

Market Cap 68.76M
Enterprise Value -16.83M

Important Dates

The last earnings date was Thursday, May 15, 2025, before market open.

Earnings Date May 15, 2025
Ex-Dividend Date n/a

Share Statistics

Pyxis Oncology has 61.95 million shares outstanding. The number of shares has increased by 38.73% in one year.

Current Share Class 61.95M
Shares Outstanding 61.95M
Shares Change (YoY) +38.73%
Shares Change (QoQ) -0.32%
Owned by Insiders (%) 6.29%
Owned by Institutions (%) 32.69%
Float 44.65M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 0.66
P/TBV Ratio 0.68
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.75, with a Debt / Equity ratio of 0.19.

Current Ratio 7.75
Quick Ratio 7.31
Debt / Equity 0.19
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -66.30% and return on invested capital (ROIC) is -31.70%.

Return on Equity (ROE) -66.30%
Return on Assets (ROA) -29.19%
Return on Invested Capital (ROIC) -31.70%
Return on Capital Employed (ROCE) -68.48%
Revenue Per Employee n/a
Profits Per Employee -$2.16M
Employee Count 44
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax -2.16M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -73.57% in the last 52 weeks. The beta is 1.15, so Pyxis Oncology's price volatility has been higher than the market average.

Beta (5Y) 1.15
52-Week Price Change -73.57%
50-Day Moving Average 1.06
200-Day Moving Average 2.28
Relative Strength Index (RSI) 51.79
Average Volume (20 Days) 564,644

Short Selling Information

The latest short interest is 7.23 million, so 11.68% of the outstanding shares have been sold short.

Short Interest 7.23M
Short Previous Month 7.13M
Short % of Shares Out 11.68%
Short % of Float 16.20%
Short Ratio (days to cover) 13.60

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -83.16M
Pretax Income -57.80M
Net Income -95.23M
EBITDA -80.55M
EBIT -83.16M
Earnings Per Share (EPS) -$1.57
Full Income Statement

Balance Sheet

The company has $105.43 million in cash and $19.84 million in debt, giving a net cash position of $85.59 million or $1.38 per share.

Cash & Cash Equivalents 105.43M
Total Debt 19.84M
Net Cash 85.59M
Net Cash Per Share $1.38
Equity (Book Value) 103.10M
Book Value Per Share 1.69
Working Capital 97.44M
Full Balance Sheet

Cash Flow

Operating Cash Flow n/a
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Pyxis Oncology does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -38.73%
Shareholder Yield -38.73%
Earnings Yield -138.50%
FCF Yield n/a

Analyst Forecast

The average price target for Pyxis Oncology is $9.00, which is 710.81% higher than the current price. The consensus rating is "Strong Buy".

Price Target $9.00
Price Target Difference 710.81%
Analyst Consensus Strong Buy
Analyst Count 5
Revenue Growth Forecast (5Y) 40.82%
EPS Growth Forecast (5Y) -3.11%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score n/a